Biotechnology

Orient Biotech

Orient Biotech released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 256.26 M, actual EPS CNY -0.49

Orient Biotech to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Orient Biotech to Release FY2025 Earnings on April 29, Pre-Market BJT

Orient Biotech released FY2025 Annual Earnings on February 27 Pre-Market (BJT), actual revenue CNY 947.38 M, actual EPS CNY -2.98

Orient Biotech released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 275.57 M, actual EPS CNY -1.8995

Orient Biotech released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 671.81 M, actual EPS CNY -1.085

Orient Biotech released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 268.73 M, actual EPS CNY -0.2585

Orient Biotech to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

Orient Biotech released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 211.13 M, actual EPS CNY -0.2564

Orient Biotech released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), actual revenue CNY 403.08 M, actual EPS CNY -0.84

Orient Biotech FY2025 Semi-Annual Earning Release on August 29, 2025 (BJT)

Orient Gene Subsidiaries Obtain Foreign Medical Device Registration Certificates

 Orient Gene Plans to Repurchase Shares to Maintain Shareholder Equity

Eastern Bio and Subsidiary Obtain Medical Device Registration Certificates

East Orient Biopharma Chairman Proposes Share Repurchase

Orient Gene's Liquid Chip Platform Put Into Use in Multiple Hospitals

Orient Biotech released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 191.95 M, actual EPS CNY -0.57

Orient Biotech FY2025 Q1 Earnings Release on April 30 After-Market BJT

Orient Biotech to Release FY2024 Earnings on April 30 After-Market (BJT), Forecast EPS CNY 0

Orient Gene Obtains EU CE Certification for COVID-19 Test Kit

688317

002022

301080

300639

300482

688399

688298

002030

300463

The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily limit up in the afternoon. LIFERIVER and DAJY had previously reached their limit up, while WONDFO BIOTECH, ACROBIOSYSTEMS, Orient Biotech, and SSSW rose over 10%

Wallstreetcn

LIFERIVER

ACROBIOSYSTEMS

Hybribio Biotech

WONDFO BIOTECH

SSSW

DAJY

maccura

Orient Biotech's subsidiary Hangzhou Danwei Biotechnology Co., Ltd. recently obtained registration certificates for two medical device products, namely the 14 types of high-risk HPV nucleic acid detection and 16/18 typing reagent kits, and the combined nucleic acid detection reagent kit for the novel coronavirus and influenza A and B viruses. The registration of these products will enrich the company's product line in the fields of HPV virus detection and respiratory virus detection, helping to expand the domestic market

Zhitong

Orient Biotech's subsidiary has obtained registration certificates for two medical device products

Orient Biotech announced that the company has completed its share repurchase, with an actual repurchase of 1.8013 million shares, accounting for 0.8935% of the total share capital. The repurchase price range was between RMB 26.45 per share and RMB 29.52 per share, with a total amount of funds used being RMB 49.9943 million. The repurchased shares will be used to maintain the company's value and shareholder rights, and will be sold through centralized bidding trading 12 months after the company discloses the repurchase results and share changes announcement

Orient Biotech: Completed the repurchase of 1.8013 million shares

Orient Biotech's wholly-owned subsidiary Healgen Scientific LLC and its holding subsidiary Hangzhou Laihe Biotechnology Co., Ltd. recently obtained multiple medical device registration certificates. These products include respiratory combined detection reagents and fully automated biochemical analyzers, which have been certified in China, the European Union, Israel, and Peru, expanding the company's product range in related markets and helping to address the testing of seasonal respiratory infections and other diseases

Orient Biotech's subsidiary obtains medical device registration certificate

Orient Biotech announced that in the first half of 2025, operating revenue was 403 million yuan, a year-on-year decrease of 3.62%. The net profit attributable to shareholders of the listed company was -163 million yuan, compared to -152 million yuan in the same period last year

Orient Biotech: Net loss of 163 million yuan in the first half of 2025

Orient Biotech and its wholly-owned subsidiary, American Hengjian and Shanghai Wanzi Health Biotechnology, recently obtained multiple medical device registration certificates, including the Influenza A/B Virus Antigen Detection Kit, Anti-MPO Antibody Detection Kit, Anti-PR3 Antibody Detection Kit, Anti-GBM Antibody Detection Kit, Healgen® Immunofluorescence Analyzer (OG-H180), and Healgen® AccuFluor Fentanyl Fluorescence Immunoassay Test Kit

Orient Biotech and its subsidiaries have obtained multiple medical device registration certificates

688313

688062

Recently, A-share listed companies such as Shijia Photons, Orient Biotech, and Mabwell have disclosed the latest information on their top ten shareholders, and the repositioning actions of well-known fund managers have also come to light. At the same time, foreign institutions such as Barclays Bank, UBS, and JP Morgan Securities have frequently increased their holdings in A-shares. The market is expected to reach a critical moment in the second half of 2025, with decision-makers anticipated to strengthen technological self-reliance and boost consumption, while financial policies will remain accommodative. Some industries with improved performance expectations for the semi-annual reports are worth paying attention to

Shijia Photons

Mabwell

Institutional Deployment: Structural Opportunities Become Market Consensus

The second-quarter portfolio adjustments of well-known fund managers show significant divergence in the pharmaceutical sector, with some fund managers increasing their positions in companies like Orient Biotech, while others choose to reduce their holdings in Mabwell. The market's view on pharmaceutical stocks mainly revolves around factors such as valuation, performance, research and development risks, and policy impacts. In addition, the military industry sector has received more attention, with institutions warning to be cautious of short-term volatility risks

Famous fund managers' second-quarter portfolio adjustments revealed: increasing positions in military industry, with divergences in the pharmaceutical sector

301033

In the first half of 2025, the portfolio adjustments of several well-known fund managers were revealed, mainly focusing on the medical and military sectors. Wan Minyuan from Rongtong Fund reduced his holdings in Orient Biotech in the first quarter and increased them in the second quarter; the China Europe Medical Health Mixed Fund managed by Grantham has newly included Medprin among its top ten circulating shareholders. Wu Xingwu from GF Fund reduced his holdings, while Chen Yunzhong increased his holdings in military stocks

Medprin

Famous fund manager's portfolio adjustment revealed, intensively participating in the medical and military sectors

Orient Biotech announced that some clients of the company and its subsidiary, American Hengjian Biotechnology Co., Ltd., recently obtained overseas medical device registration certificates or production and sales licenses for several respiratory combination detection products. At the same time, the holding subsidiary Beijing Xinxing Sihuan Biotechnology Co., Ltd. completed a product change registration. This move will help expand domestic and international markets

Orient Biotech has obtained the medical device registration certificate

Orient Biotech(688298.SH)